A review of the evidence and cost of therapies for cutaneous lupus erythematosus

J. D. Rosen, S. Paul, A. Maderal

Research output: Contribution to journalReview articlepeer-review


Cutaneous lupus erythematosus (CLE)—a common presentation of lupus erythematosus—may exist independently or as a part of the systemic manifestations of systemic lupus erythematosus. The effects of living with and treating a chronic condition such as CLE can be debilitating to a patient's health and finances. The management of patients with CLE is made particularly challenging by poor compliance, limited therapeutic options, scarcity of evidence supporting their use, and significant differences in costs of medications. Effective management of CLE should center on prevention, individualized treatment regimens, and a mutual understanding of the challenges that patients with CLE face. This article seeks to provide an overview of the efficacy, safety, and cost of therapeutic options for CLE.

Original languageEnglish (US)
Pages (from-to)799-805
Number of pages7
Issue number7
StatePublished - Jun 1 2019


  • Cutaneous lupus erythematosus
  • lupus
  • systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'A review of the evidence and cost of therapies for cutaneous lupus erythematosus'. Together they form a unique fingerprint.

Cite this